FDA DEVICE FACTS
cmAngio® V2.0
Curemetrix, Inc.
FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。
Indications for use
cmAngio, a proprietary artificial intelligence (Al)-based software is intended to process Full Field Digital Mammogram (FFDM) and Digital Breast Tomosynthesis (DBT) screening mammograms to aid qualified interpreting physicians in the identification, visualization, and contextualization of Breast Arterial Calcifications (BAC), an incidental finding. The software functionalities include: * Detection of BAC at both the study and breast level, + Localization of BAC segments by marking detected regions on image thumbnails, + Measurement of Study-level BAC Length and View-level BAC Length, representing the extent of detected BAC findings. * Normalization of BAC length and comparison against an age-matched Reference Library to report and display an Age-based BAC Percentile, and «Reporting of Age-based BAC Prevalence based on the same Reference Library. The software is intended to be used by qualified interpreting physicians in parallel with breast cancer screening mammography workflow. The device is not intended for primary interpretation of digital mammography images as used for breast cancer detection. The device results should not be used alone to make any diagnosis and/or treatment decisions.
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。